|Table of Contents|

Preliminary study on the value of "radiation-targeted therapy-immunotherapy" combination in the third-line treatment of microsatellite stable metastatic colorectal cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 10
Page:
1843-1847
Research Field:
Publishing date:

Info

Title:
Preliminary study on the value of "radiation-targeted therapy-immunotherapy" combination in the third-line treatment of microsatellite stable metastatic colorectal cancer
Author(s):
ZHANG Qun; HU Jing; QIAN Xiaoping; LI Li
The Comprehensive Cancer Centre,Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Jiangsu Nanjing 210008,China.
Keywords:
metastatic colorectal cancer; combination therapy; microsatellite stable; radiotherapy; targeted therapy; immunotherapy
PACS:
R735.3
DOI:
10.3969/j.issn.1672-4992.2024.10.014
Abstract:
Objective:To investigate the clinical value and side effects of "radiation-targeted therapy-immunotherapy" combined therapy in the third-line treatment of patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).Methods:Patients with MSS subtype mCRC who received the above-combined treatment mode in our cancer center were retrospectively analyzed,and the treatment efficacy and side effects were evaluated.Results:Among the 5 patients with MSS subtype mCRC who received the "radiation-target therapy-immunotherapy" combined treatment mode,the efficacy evaluation was the partial response (PR) in 1 case,stable disease (SD) in 2 cases,and progression disease (PD) in 2 cases,with a disease control rate (DCR) of 60.0%(3/5).In terms of side effects,none of the 5 patients had grade III-IV side effects.Conclusion:The "radiation-targeted therapy-immunotherapy" combination mode is expected to provide a new strategy for the third-line treatment of mCRC with refractory MSS subtypes,although this conclusion still needs to be verified with a larger sample size.

References:

[1] CAO W,CHEN HD,YU YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020［J］.Chin Med J (Engl),2021,134(7):783-791.
[2] GANESH K,STADLER ZK,CERCEK A,et al.Immunotherapy in colorectal cancer:rationale,challenges and potential［J］.Nat Rev Gastroenterol Hepatol,2019,16(6):361-375.
[3] MAYER RJ,VAN CUTSEM E,FALCONE A,et al.RECOURSE Study Group.Randomized trial of TAS-102 for refractory metastatic colorectal cancer［J］.N Engl J Med,2015,372(20):1909-1919.
[4] LI J,QIN S,XU RH,et al.Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer:the FRESCO randomized clinical trial［J］.JAMA,2018,319(24):2486-2496.
[5] GROTHEY A,VAN CUSTEM E,SOBRERO A,et al.CORRECT Study Group.Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT):an international,multicentre,randomised,placebo-controlled,phase 3 trial［J］.Lancet,2013,381(9863):303-312.
[6] ANDRE T,SHIU KK,KIM TW,et al.KEYNOTE-177 investigators.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer［J］.N Engl J Med,2020,383(23):2207-2218.
[7] LE DT,URAM JN,WANG H,et al.PD-1 blockade in tumors with mismatch-repair deficiency［J］.N Engl J Med,2015,372(26):2509-2520.
[8] O' NEIL BH,WALLMARK JM,LORENTE D,et al.Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma［J］.PLoS One,2017,12(12):e0189848.
[9] LI DD,TANG YL,WANG X.Challenges and exploration for immunotherapies targeting cold colorectal cancer［J］.World J Gastrointest Oncol,2023,15(1):55-68.
[10] GANESH K.Optimizing immunotherapy for colorectal cancer［J］.Nat Rev Gastroenterol Hepatol,2022,19(2):93-94.
[11] ALIMOHAMMADI M,GHAFFARI-NAZARI H,ALIMOHAMMADI R,et al.Radiotherapy combination:insight from tumor immune microenvironment (TIME)［J］.Avicenna J Med Biotechnol,2023,15(4):209-215.
[12] PARIKH AR,SZABOLCS A,ALLEN JN,et al.Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial［J］.Nat Cancer,2021,2(11):1124-1135.
[13] RAMJIAWAN RR,GRIFFIOEN AW,DUDA DG.Anti-angiogenesis for cancer revisited:Is there a role for combinations with immunotherapy［J］.Angiogenesis,2017,20(2):185-204.
[14] FUKUOKA S,HARA H,TAKAHASHI N,et al.Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label,dose-escalation,and dose-expansion phase Ib trial (REGONIVO,EPOC1603)［J］.J Clin Oncol,2020,38(18):2053-2061.
[15] YI M,JIAO D,QIN S,et al.Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment［J］.Mol Cancer,2019,18(1):60.
[16] LI Q,CHENG X,ZHOU C,et al.Fruquintinib enhances the antitumor immune responses of anti-programmed death receptor-1 in colorectal cancer［J］.Front Oncol,2022,12:841977.
[17] WANG Y,WEI B,GAO J,et al.Combination of fruquintinib and anti-PD-1 for the treatment of colorectal cancer［J］.J Immunol,2020,205(10):2905-2915.
[18] GOU M,QIAN N,ZHANG Y,et al.Fruquintinib in combination with PD-1 inhibitors in patients with refractory non-MSI-H/pMMR metastatic colorectal cancer:a real-world study in China［J］.Front Oncol,2022,12:851756.

Memo

Memo:
National Natural Science Foundation of China(No.82303970）；国家自然科学基金青年项目（编号：82303970）
Last Update: 1900-01-01